Cardiovascular Disease Therapy

Utility of endothelin-1 receptor blockade for heart failure patients reviewed

Published in Drug Week, February 6th, 2004

The utility of endothelin-1 receptor antagonist therapy for heart failure has been reviewed.

"Endothelin-1 is a vasoconstrictor peptide playing an important role in the pathophysiology of heart failure," cardiologists in France explained. "Endothelin-1 acts after fixation to two specific receptors: type A, responsible for vasoconstriction and type B, at the start of transient vasodilation and participating in clearance of the hormone."

"The experimental results in various animal models have demonstrated beneficial hemodynamic and clinical effects of the mixed or specific antagonists of the type A receptor," noted P. de Groote and colleagues at the...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Drug Week

Source: Drug Week (2004-02-06)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry